Systemic Antibacterial and Antifungal Drugs: Susceptibility Test Interpretive Criteria Labeling for NDAs and ANDAs
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
December 13, 2017
May 5, 2020
a071fec6-d1c9-41d8-bbbf-4f71788c7e7f
Related Documents
Allergic Rhinitis: Developing Drug Products for Treatment Guidance for Industry
Guidance DocumentSeptember 6, 2018Center for Drug Evaluation and Research
Recurrent Herpes Labialis: Developing Drugs for Treatment and Prevention
Guidance DocumentNovember 8, 2017Center for Drug Evaluation and Research
Migraine: Developing Drugs for Acute Treatment
Guidance DocumentFebruary 16, 2018Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.